189 related articles for article (PubMed ID: 6282207)
1. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus.
Shigeta S; Yokota T; Iwabuchi T; Baba M; Konno K; Ogata M; De Clercq E
J Infect Dis; 1983 Mar; 147(3):576-84. PubMed ID: 6300257
[TBL] [Abstract][Full Text] [Related]
3. Influence of various experimental conditions on the inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on varicella-zoster virus replication in cell culture.
Baba M; Shigeta S; De Clercq E
Tohoku J Exp Med; 1984 Aug; 143(4):441-9. PubMed ID: 6093286
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
5. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs.
De Clercq E; Walker RT
Pharmacol Ther; 1984; 26(1):1-44. PubMed ID: 6099893
[TBL] [Abstract][Full Text] [Related]
8. Serum and urine concentrations of oral bromovinyldeoxyuridine in humans as monitored by a bioassay system based on varicella-zoster virus focus inhibition.
Baba M; Shigeta S; De Clercq E
J Med Virol; 1987 May; 22(1):17-23. PubMed ID: 3035076
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides.
Balzarini J; McGuigan C
Biochim Biophys Acta; 2002 Jul; 1587(2-3):287-95. PubMed ID: 12084470
[TBL] [Abstract][Full Text] [Related]
10. The development of BVDU: An odyssey.
De Clercq E
Antivir Chem Chemother; 2023; 31():20402066231152971. PubMed ID: 36710501
[TBL] [Abstract][Full Text] [Related]
11. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
12. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
Yokota T; Konno K; Shigeta S; De Clercq E
Mol Pharmacol; 1984 Sep; 26(2):376-80. PubMed ID: 6090888
[TBL] [Abstract][Full Text] [Related]
13. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T
Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
15. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E
J Antimicrob Chemother; 1984 Aug; 14 Suppl A():85-95. PubMed ID: 6092320
[TBL] [Abstract][Full Text] [Related]
16. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
[TBL] [Abstract][Full Text] [Related]
17. Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds.
Balzarini J; De Clercq E; Verbruggen A; Crumpacker C; Ayusawa D; Seno T
Anticancer Res; 1986; 6(5):1077-84. PubMed ID: 2432829
[TBL] [Abstract][Full Text] [Related]
18. Therapy of varicella-zoster virus infection--mechanism of action of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Shigeta S; Yokota T; De Clercq E
Antiviral Res; 1985; Suppl 1():35-44. PubMed ID: 3002264
[No Abstract] [Full Text] [Related]
19. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.
Andrei G; Snoeck R; Reymen D; Liesnard C; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):318-29. PubMed ID: 7649195
[TBL] [Abstract][Full Text] [Related]
20. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
